New Zealand Breast Cancer Therapeutics Market Report 2022 to 2030

New Zealand Breast Cancer Therapeutics Market Analysis

$ 3999

The New Zealand breast cancer therapeutics market is witnessing a growth of $xx Bn in 2022 with a CAGR of xx% for the year 2022-2030 and $xx Bn in 2030 due to market drivers like increasing investments in breast cancer treatments and growing awareness about breast cancer. The market is segmented by therapy, by cancer type, and by distribution channel. Alaron Products Limited, Bristol-Myers Squibb Co., and Eli Lilly and Co. are major companies in the New Zealand breast cancer therapeutics market.

ID: IN10NZPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: New Zealand AUTHOR: Parul Choudhary

Buy Now

New Zealand Breast Cancer Therapeutics Market Executive Analysis

The New Zealand breast cancer therapeutics market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. Vote Health will receive new funds of $14.9 Bn from the New Zealand Budget 2022 over the course of the following four years, with up to $13.4 Bn going toward running costs and $1.5 Bn going toward construction expenditures. The new health entities will get $1.8 Bn in 2022–2023 and an additional $1.3 Bn in 2023–2024 from Budget 2022 to manage past and upcoming cost challenges. Additionally, up to $91.88 Mn is included in the budget for 2022 to guarantee that the New Zealand Ministry has the capacity and aptitude necessary for its extended protection role in the new healthcare system. This will increase the Ministry's capacity to deliver excellent strategic health policy guidance. The capital investment for health infrastructure included in Budget 2022 totals $1.307 Bn over four years, supporting the completion of new infrastructure projects and developing other initiatives. This will make it possible to support a solid pipeline of projects that are ready for investment in the upcoming years.

In New Zealand, 6% of breast cancer cases are seen in people under the age of 40. Even though it is rare, men can develop breast cancer. In New Zealand, about 25 men are diagnosed annually. Overall, 85% of breast cancer patients live for 10 years or more (95% if the disease is found on a screening mammogram), but unfortunately, more than 650 women pass away from the illness each year. Female breast cancer mortality decreased by 21.5 % in the past ten years, despite registration rates for the disease remaining largely steady between 1999 and 2009. Over time, New Zealand's breast cancer trends have mirrored global trends. The reduction in mortality is typically attributed to earlier detection of the disease through breast cancer screening as well as increased use and efficiency of adjuvant therapy.

The two cancers for which New Zealand runs a national population-based screening programme are breast cancer and cervical cancer. Through the free nationwide programme managed by BreastScreen Aotearoa, the Ministry of Health encourages all eligible women aged 45 to 69 to have screening mammography. Women who are later diagnosed with breast cancer must receive the best care possible, which is one of the fundamental elements of a successful screening programme. National policy & quality standards have been developed by the national screening programme.

Market Dynamics

Market Growth Drivers

The rise in breast cancer incidence and the beginning of investments in the development of technologies for cancer treatment are two major reasons driving the growth of the breast cancer therapeutics market in New Zealand. Due to the major firms' increased use of strategic marketing alliances, new product advancements, and acquisitions to boost their market positions and gain an advantage over rivals, the New Zealand breast cancer therapeutics market is projected to grow even more.

Market Restraints

New Zealand breast cancer therapeutics are impeded by issues like high healthcare expenses, a lack of qualified medical oncologists, and labour-intensive and complicated therapy procedures.

Competitive Landscape

Key Players

New Zealand Pharmaceuticals Limited (NZL)
PHARMAC (NZL)
Alaron Products Limited (NZL)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

Given that New Zealand's healthcare system is publicly funded, those who qualify can typically receive free breast cancer treatment. The rules and recommendations for breast cancer screening, diagnosis, and treatment are established by New Zealand's Ministry of Health. Free mammograms are provided to women between the ages of 45 and 69 by the national breast cancer screening programme BreastScreen Aotearoa every two years. The newest research and industry best practices have also been included in guidelines for the care and treatment of breast cancer. In New Zealand, there are numerous organisations and support groups that offer guidance and assistance to those afflicted by breast cancer.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.